

**Supplement 2 – Reasons for exclusion of screened articles**

<b>Study</b>	<b>Reason for exclusion</b>
Hui-Chou HG et al, 2019(1)	Out of topic
Dolcino M et al, 2019(2)	Out of topic
Leonardi L et al, 2019(3)	Out of topic
Souk JW et al, 2019(4)	Case report
Berk-Krauss J et al, 2018(5)	Case report
Dhaliwal K et al, 2018(6)	Statistical analysis not performed
Garrido-Rfós AA et al, 2018(7)	Case report
Hoverson K et al, 2018(8)	Out of topic
Motegi SI et al, 2018(9)	Case series (n=2)
Blaise S et al, 2017(10)	Case report
Rosholm Comstedt L et al, 2017(11)	Out of topic
Žebryk P et al, 2016(12)	Review
Hughes M et al, 2016(13)	Review
Walker HW et al, 2015(14)	Out of topic
Nielsen JB et al, 2014(15)	Language
Herrick A et al, 2014(16)	Review
Herrick AL, 2013(17)	Review
Wall LB et al, 2012(18)	Case report
Barkmeier-Kraemer J et al, 2011(19)	Out of topic
Pöllmann W et al, 2008(20)	Out of topic
Srinivasan S et al, 2007(21)	Out of topic
Manrique D, 2005(22)	Out of topic
Pöllmann W et al, 2005(23)	Out of topic
Medical Advisory Secretariat, 2005(24)	Out of topic
Konstanzer A et al, 1993(25)	Out of topic

1. Hui-Chou HG, Thakkar MY, Means KR, Jr., Higgins JP. A Prospective Pilot Study of Vascular Assessment of the Upper Extremity With Laser Angiography. *Hand* (New York, NY) 2019;1558944719837023.
2. Dolcino M, Tinazzi E, Puccetti A, Lunardi C. In Systemic Sclerosis, a Unique Long Non Coding RNA Regulates Genes and Pathways Involved in the Three Main Features of the Disease (Vasculopathy, Fibrosis and Autoimmunity) and in Carcinogenesis. *Journal of clinical medicine* 2019;8(3).
3. Leonardi L, Haggiag S, Petrucci A, Lispi L. Electrophysiological abnormalities in iatrogenic botulism: Two case reports and review of the literature. *Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia* 2019;60:138-41.
4. Souk JW, Kim HS. Effects of botulinum toxin injection on systemic sclerosis-related digital ulcers. *The Korean journal of internal medicine* 2019;34(5):1169-70.
5. Berk-Krauss J, Christman MP, Franks A, Sicco KL, Liebman TN. Botulinum toxin for treatment of Raynaud phenomenon in CREST syndrome. *Dermatology online journal* 2018;24(12).

6. Dhaliwal K, Griffin M, Denton CP, Butler PEM. The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes. *BMJ case reports* 2018;2018.
7. Garrido-Rios AA, Gonzalez-Olivares M, Navarro-Vidal B, Martinez-Moran C, Borbujo J. Ischaemic ulcers on the toes secondary to Raynaud phenomenon in a patient with systemic sclerosis successfully treated with botulinum toxin. *Clinical and experimental dermatology* 2018;43(4):503-05.
8. Hoverson K, Love T, Lam TK, Marquart JD. A novel treatment for limited mouth opening due to facial fibrosis: A case series. *Journal of the American Academy of Dermatology* 2018;78(1):190-92.
9. Motegi SI, Sekiguchi A, Saito S, Ishibuchi H, Kishi C, Yasuda M, et al. Successful treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: Assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary. *The Journal of dermatology* 2018;45(3):349-52.
10. Blaise S, Roustit M, Forli A, Imbert B, Cracowski JL. Non-healing ischaemic digital ulcer in a systemic sclerosis patient: a challenging clinical case. *International wound journal* 2017;14(6):978-81.
11. Rosholt Comstedt L, Svensson A, Hesselstrand R, Lehti L, Troilius Rubin A. Effects of intense pulsed light in microstomia in patients with systemic sclerosis: A pilot study. *Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology* 2017;19(3):143-48.
12. Zebryk P, Puszczewicz MJ. Botulinum toxin A in the treatment of Raynaud's phenomenon: a systematic review. *Archives of medical science : AMS* 2016;12(4):864-70.
13. Hughes M, Herrick AL. Raynaud's phenomenon. *Best practice & research Clinical rheumatology* 2016;30(1):112-32.
14. Walker HW, Lee MY, Bahroo LB, Hedera P, Charles D. Botulinum toxin injection techniques for the management of adult spasticity. *PM & R : the journal of injury, function, and rehabilitation* 2015;7(4):417-27.
15. Nielsen JB, Hvid L, Olesen AB. [Marked effect of botulinum toxin A for severe toe digital ulcers in a patient with systemic sclerosis]. *Ugeskrift for laeger* 2014;176(8a):V08130527.
16. Herrick A, Muir L. Raynaud's phenomenon (secondary). *BMJ clinical evidence* 2014;2014.

17. Herrick AL. Management of Raynaud's phenomenon and digital ischemia. Current rheumatology reports 2013;15(1):303.
18. Wall LB, Stern PJ. Nonoperative treatment of digital ischemia in systemic sclerosis. The Journal of hand surgery 2012;37(9):1907-9.
19. Barkmeier-Kraemer J, Lato A, Wiley K. Development of a speech treatment program for a client with essential vocal tremor. Seminars in speech and language 2011;32(1):43-57.
20. Pollmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS drugs 2008;22(4):291-324.
21. Srinivasan S, Slomovic AR. Sjogren syndrome. Comprehensive ophthalmology update 2007;8(4):205-12.
22. Manrique D. Application of botulinum toxin to reduce the saliva in patients with amyotrophic lateral sclerosis. Brazilian journal of otorhinolaryngology 2005;71(5):566-9.
23. Pollmann W, Feneberg W, Steinbrecher A, Haupts MR, Henze T. [Therapy of pain syndromes in multiple sclerosis -- an overview with evidence-based recommendations]. Fortschritte der Neurologie-Psychiatrie 2005;73(5):268-85.
24. Intrathecal baclofen pump for spasticity: an evidence-based analysis. Ontario health technology assessment series 2005;5(7):1-93.
25. Konstanzer A, Ceballos-Baumann AO, Dressnandt J, Conrad B. [Local injection treatment with botulinum toxin A in severe arm and leg spasticity]. Der Nervenarzt 1993;64(8):517-23.